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Linda Kaerlev1,2*, Maria Iachina1,2, Jesper Holst Pedersen3, Anders Green1,2 and Bente Mertz Nørgård1,2Abstract
Background: CT screening for lung cancer has recently been shown to reduce lung cancer mortality, but screening
may have adverse mental health effects. We calculated risk ratios for prescription of anti-depressive (AD) or
anxiolytic (AX) medication redeemed at Danish pharmacies for participants in The Danish Lung Cancer Screening
Trial (DLCST).
Methods: The DLCST was a randomized clinical trial which comprised 4,104 former or present smokers who were
randomized from 12 May 2004 to 20 June 2006 to either CT scan of the chest, lung-function test and filling in
questionnaires annually for five years in the period 1 April 2006–31 March 2010 (n = 2,052), or to a control group
(n = 2,052) receiving similar procedures except CT scan. We used CT scan intervention group versus control group
status as exposure. The follow-up period for use of AD or AX was three years. Baseline data on civil status,
socioeconomic status, and co-morbidity as well as outcome data on AD and AX were obtained by linkage to
national registries.
Results: The intervention and the control groups did not differ by age, gender, civil status, socio-economic
position, co-morbidity index or former use of AD or AX. The adjusted risk ratio for at least one recipe of AD or AX
in the CT intervention group during follow-up was not increased when adjusting for previous use of AD or AX, HR
1.00, 95 % CI (0.90-1.12). Similar results were seen when excluding subjects using AD or AX in a four-month or two-
year period before baseline, when analyzing AD and AX separately, or requiring at least two recipes.
Conclusions: We found no indications that participation in a lung cancer CT-screening program increases the risk
of specific adverse mental health outcomes.
Trial registration: Clinical Trials.gov Protocol Registration System (NCT00496977).
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Screening for serious diseases in occupational or lifestyle
related target groups has been more common in the re-
cent years. The recent demonstration of a reduction in
lung cancer specific mortality by more than 20 per cent
and an overall 7 % reduced mortality following CT
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unrestricted use, distribution, and reproductiohave great implications for health practice. [1] Before a
general implementation of CT screening, it will be ne-
cessary also to clarify any adverse effects of CT screen-
ing. While experiencing a cancer diagnosis obviously
may cause anxiety or even depression, the risk of devel-
oping depressive or anxiety symptoms following cancer
screening has only been investigated in a few studies. [2-
4] Participation in screening might be related to gender,
age, co-morbidity, and social factors that are related
both to tobacco smoking as well as later mental health.
[5-8] Therefore, the possibility of biased risk estimates
of developing depressive or anxiety symptoms might
occur unless such potential confounding factors areLtd; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/2.0), which permits
n in any medium, provided the original work is properly cited.
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studies of participation bias, among volunteers in med-
ical trials have shown that participants in screening pro-
grams, in general, have a more robust personality and
less psychopathology compared with smokers in the
general population. [6,9-13] This study aimed to exam-
ine psychological adverse effects in a Danish randomized
clinical trial (The Danish Lung Cancer Screening Trial
(DLCST)) with the calculation of risk ratios for prescrip-
tion of anti-depressive (AD) or anxiolytic (AX) medica-
tion according to CT screening intervention or control
group status with adjusting for potential confounding
factors at baseline.
Methods
The DLCST
The study is based on the DLCST - a randomized clin-
ical trial - with the overall aim to assess whether CT-
screening of heavy tobacco smokers or ex-smokers with
a history of at least 20 pack-years can reduce mortality
from lung cancer. A total of 4,104 volunteers aged be-
tween 50 and 70 years, were included in the DLCST,
with randomization at baseline - a specific date during
the period 12 May 2004 until 20 June 2006- to either an
intervention group (2,052 persons) or a control group
(2,052 persons) followed by four annual screening
rounds in the period 1 April 2006–31 March 2010. [5].
A baseline CT scan was performed in all participants of
the CT intervention group.
Pulmonary nodules were classified according to size,
morphology and growth, and the assessment was validated
by two radiologists. [5] At base line (1) nodules smaller
than 5 mm and calcified (benign) nodules were tabulated,
(2) non-calcified nodules between 5 and 15 mm were
rescanned after three months. If the nodule increased in
size or was larger than 15 mm the participant was referred
for diagnostic procedures. The growth of nodules was
assessed by both linear measurement and volumetric ana-
lysis. [14] On an annual basis the CT intervention group
was offered a CT scan and completed annual lung func-
tion tests together with questionnaires on smoking habits,
health status, psychosocial factors, and quality of life
issues. The control group had identical procedures as the
screening group, but without CT scans.
Persons with a permanent address in Denmark have a
unique 10-digit Civil Registration Number (CPR), which
has been assigned to each Danish resident since 1968.
The number includes information on birthday and sex,
and it is used by all authorities for registration purposes.
We used the CPR to link the DLCST project data with
public registries including The Danish Civil Registration
System [15], The Danish National Patient Register [16],
and with public registries developed by StatisticsDenmark such as The Household and Family Statistics
(based on The Danish Civil Registration System) as well
as The personal income statistics [17] and The Danish
National Prescription Registry of the Danish Medicines
Agency. [18].
Both the intervention group and the control group in the
DLCST were followed-up for three years for use of AD or
AX, counted from the baseline date of randomization in
the DLCST.
Demographic characteristics and co-morbidity of
participants
The Danish Civil Registration System contains informa-
tion on gender, addresses, dates of birth, and death and
migration for every person who is or has been a Danish
resident at any time between 1968 and the present. Infor-
mation on civil status and socio-economic position at
randomization (study baseline) was obtained from public
registries in Statistics Denmark. Civil status was defined as
living alone versus all others. Socio-economic position
(SES) was defined by level of yearly income and included
in the analyses as a categorical variable in three categories
(below DKK 250,000, DKK 250–350,000, and above DKK
350,000). Information on co-morbidity was obtained from
the NPR with calculation of a slight modification of the
Charlson Co-morbidity Index (CCI). [19,20].
The CCI was re-coded into a categorical variable (0, 1,
and above 1 point on the CCI scale). Smoking status at
baseline as a categorical variable (current or former
smoker) was used as a confounder in supplementary
analyses.
Measures of outcome
AD and AX are only available by prescription in Den-
mark. Using the unique PIN, we obtained complete in-
formation about redeemed AD and AX prescriptions by
linkage to The Danish National Prescription Registry.
[18] This register covers all pharmacies in Denmark and
classifies prescribed pharmaceuticals according to the
Anatomical Therapeutic Chemical classification system
(ATC) at the level of the generic pharmaceutical. We
used prescription of one or more of the following drugs
to define the endpoints for the present study: The AD
group comprised the overall ATC-group “N06A”, includ-
ing tricyclic antidepressants (TCA, ATC code N06AA),
selective serotonin reuptake inhibitors (SSRI, ATC code
N06AB), noradrenalin reuptake inhibitors (NARI, ATC
code N06AX) and monoamine oxidase inhibitors
(MAO-inhibitors, ATC codes N06AF and N06AG). [21].
Lithium salts are mostly prescribed for bipolar
affective disorders and were not included. Zyban has
both an anti-depressive effect (ATC code N 06 AX 12)
and is used as a smoking-cessation drug. However, none
of the DLCST participants received prescribed Zyban in
Table 1 Descriptive characteristics of participants of the
DLCST at baseline in 2004
Characteristics Respondents Intervention Control p-
valueN=4,104 N=2,052 N=2,052
Gender, women,
number, (%)
4,104 905 (44.10) 932 (45.42) 0.397
Mean age, years 4,104 57.35 57.31 0.807
Age group (above mean:
57.3 years) (%)
4,104 1,001 (48.78) 972 (47.37) 0.365
Civic status, living alone,
number, (%)
4,076 586 (28.58) 587 (28.60) 0.980
Mean income
per year (DKK)
4,100 316,910 315,814 0.859
SES group, number, (%) 4,100
Below 250,000 DKK/year 754 (36.74) 759 (36.99)
250–350,000 DKK/year 650 (31.68) 643 (31.34)
Above 350,000 DKK/year 648 (31.58) 650 (31.68) 0.972
Charlson co-morbidity
index at baseline,
number, (%)
4,104
0 1,717 (83.67) 1,693 (82.50) 0.336
1 235 (11.45) 238 (11.60)
>1 100 (4.87) 121 (5.90)
Prescription of AD or AX
medication at least once
during the 4 months
period before baseline,
number, (%)
4,104 269 (13.11) 277 (13.50) 0.713
Prescription of AD or AX
medication at least once
during the 2 years period
before baseline,
number, (%)
4,104 483 (23,54) 502 (24,46) 0.487
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included in the outcome. The AX group comprised the
overall ATC group “NO5B”: Benzodiazepine derivatives
(ATC code N05BA), Diphenylmethane derivatives (ATC
code N05BB), Carbamates (ATC code N05BC), Dibenzo-
bicyclo-octadiene derivatives (ATC code N05BD), Azas-
pirodecanedione derivatives (ATC code N05BE), and
other anxiolytic medications (ATC code N05BX).
According to guidelines from the Danish health au-
thorities the first-line drug for anxiety disorders in Den-
mark is SSRI antidepressants. Using prescription of AD
or AX as a proxy for medical conditions, without infor-
mation of the underlying medical condition on the
recipes to clearly separate depressive disorders from
anxiety disorders, did not allow us to conclude on separ-
ate analyses of AD and AX. We have thus presented the
results for the analysis of AD or AX as our main results.
Analysis
First, we compared the screening intervention group
with the controls at baseline with respect to demo-
graphic characteristics with chi-squared tests, except for
continuous variables, which were compared between the
groups with Students t-test. Secondly, we analyzed the
risk ratio for prescription of AD or AX medication,
redeemed at pharmacies at least once during a three year
follow-up period, from baseline by proportional hazard
regression with adjustment for use of AD and AX in the
previous four months before baseline. Thirdly, we ana-
lyzed the risk ratio for prescription of AD or AX medi-
cation at least once during a three year follow-up period
from baseline with exclusion at baseline of users of AD
and AX in the previous four months before baseline. In
addition, we performed extra analyses by extending the
previous use of AD or AX to a two year period, by either
analyzing AD and AX separately, or requiring at least
two recipes.
The follow-up ended at the date of the prescription of
the medication under study, the date of death, date of
emigration, date of disappearance, date of a diagnosis of
lung cancer, or after 3 years of follow-up for each indi-
vidual, whichever came first. The Person-time at risk
was calculated for each individual. The time during
follow-up was counted in days.
Hazard ratios (HR) with 95 % confidence intervals
(CIs) were calculated with adjustment for gender, age,
civil status, SES, and CCI at baseline, and previous pre-
scription of AD or AX.
In a sub-analysis, and due to the limited statistical
power, we used logistic regression to test whether the
persons diagnosed with lung cancer in the intervention
group more often had used AD or AX compared with
persons diagnosed with lung cancer in the control
group.Ethical aspects
The Danish Data Protection Agency and the Danish
Medicines Agency approved the present study (J.nr.
2008-41-2764). The DLCST was approved by the Ethical
Committee of Copenhagen County on January 31, 2003
and funded in full by the Danish Ministry of Interior
and Health on June 23, 2004. Approval of data manage-
ment in the trial was obtained from the Danish Data
Protection Agency on February 11, 2005. The trial is
registered in Clinical Trials.gov Protocol Registration
System (identification no. NCT00496977).
All participants gave written informed consent to par-
ticipation in the Danish Lung Cancer Screening Trial,
which was approved by the Ethical Committee of Co-
penhagen County on January 31, 2003.
Results
A total of 4,104 persons were randomized into the inter-
vention (2,052) or control group (2,052). Characteristics
of the cohort are given in Table 1.
Table 2 Hazard ratio (HR) for use of antidepressants or
anxiolytic drugs in the intervention group compared with
controls adjusted for former use of AD or AX, and other
confounders
Relative risk estimates
N, (%) Adj. HR 95 % CI
Intervention versus control status
Control 644 (31.38) 1.00 Reference
Intervention 634 (30.90) 1.00 0.90 1.12
Possible confounders:
Gender
Men 561 (43.90) 1.00 Reference
Women 717 (56.10) 1.36 1.21 1.53
Age
≤ mean age 57.3 years 685 (32.14) 1.00 Reference
>mean age 57.3 years 593 (30.06) 0.92 0.82 1.03
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group did not statistically differ significantly at baseline at
the time of randomization with respect to gender, mean
age, age group above 57.3 years of age, civil status with
percentage living alone, SES mean income, SES - percent-
age within the lowest, the middle, or within the highest in-
come group, percentage with CCI above 1 at the time of
randomization, or with respect to percentage having either
AD or AX medication prescribed at least once during the
four months period before baseline, or at least once during
the two years period before baseline (Table 1).
Observations were censored if the participant died
(n = 121; 67 in the intervention group, 54 controls), dis-
appeared (1 in the intervention group), or emigrated
(n = 28; 14 in the intervention group, 14 controls) during
follow-up, or were diagnosed with lung cancer (n = 92;
68 in the intervention group, 24 controls). The mean
follow-up time with standard deviation (SD) was 854
(SD 404) days for the intervention group and 851 days
(SD 409) for controls, and the median follow-up time
was 1096 days (3 years) for both groups.
Altogether 30.90 % (n = 634) of the intervention group
and 31.38 % (n = 644) of the controls have had at least
one redeemed prescription of AD or AX during follow
up (former users not excluded), Pearson chi2 = 0.1136,
Pr = 0.736.
The unadjusted risk estimates for AD or AX in the
intervention group and in the control group are shown in
Figure 1.
The risk of at least one redeemed prescription of AD or
AX among CT scan screened subjects during follow-up
according to age group, gender, civil status, SES group,
and CCI group, and without exclusion at baseline of
former users of AD and AX in the previous four months
before baseline is provided in Table 2. No differences0.
00
0.
25
0.
50
0.
75
1.
00
0 500 1000
in days
intervention group  control group
Kaplan-Meier estimates
Figure 1 Unadjusted risk estimates for AD or AX in the
intervention group (2) and in the control group (1).between the two groups were seen, neither when adjusting
for previous use of AD or AX, (HR 1.00, 95 % CI 0.90-
1.12), nor when excluding subjects using AD or AX in a
four months period before baseline HR 1.01, 95 % CI
(0.88-1.17) (Table 3) or excluding a two year period before
baseline, when analyzing AD and AX separately, or requir-
ing at least two recipes (data not shown).
Supplementary analyses with further adjustment for
smoking status at baseline (current or former smoker)
were performed, and no significant differences in the HR
for AD or AX were seen before and after adjustment.
Similarly, the HRs for the covariates only changed
slightly in Table 2 and 3 after further adjustment for
smoking status at baseline.
Among the 92 persons with a lung cancer diagnosis (68
in the CT scan intervention group; 24 in the control
group), 52.4 % of the control group and 37.1 % of theCivil status
Living together 806 (63.46) 1.00 Reference
Living alone 464 (36.54) 1.26 1.12 1.42
Social status (SES)
Low 576 (38.07) 1.00 Reference
Middle 397 (30.70) 0.86 0.80 0.93
High 305 (23.50) 0.43 0.37 0.49
Charlson Co-morbidity index (CCI)
0 985 (28.89) 1.00 Reference
1 197 (41.65) 1.25 1.14 1.37
> 1 96 (43.44) 2.50 2.38 2.62
Prescription of AD or AX at least once during the 4 months
period before baseline
No 775 (21.78) 1.00 Reference
Yes 503 (92.12) 18.52 16.12 21.27
Total 1,278 (31.14)
Table 3 Hazard ratio (HR) for use of antidepressants or
anxiolytic drugs in the intervention group compared with
controls, with exclusion at baseline of former users of AD
or AX, and adjusted for confounders
Relative risk estimates
N, (%) Adj. HR 95 % CI
Intervention versus control status
Control 385 (21.69) 1.00 Reference
Intervention 390 (21.87) 1.01 0.88 1.17
Possible confounders:
Gender
Men 367(47.35) 1.00 Reference
Women 408(52.65) 1.69 1.45 1.96
Age
≤ mean age 57.3 years 415 (53.55) 1.00 Reference
>mean age 57.3 years 360 (46.45) 0.88 0.76 1.03
Civil status
Living together 518 (67.19) 1.00 Reference
Living alone 253 (32.81) 1.30 1.11 1.52
Social status (SES)
Low 313 (40.39) 1.00 Reference
Middle 253 (32.65) 0.84 0.77 0.92
High 209 (26.97) 0.42 0.34 0.50
Charlson Co-morbidity index (CCI)
0 609 (78.58) 1.00 Reference
1 111 (14.32) 1.35 1.20 1.52
> 1 55 (7.10) 2.70 1.13 4.27
Total 775 (21.78)
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sons without a cancer diagnosis 31.2 % of the control
group and 30.7 % of the intervention group had used AD
and AX, odds ratio 0.48; 95 % CI (0.17-1.37). Thus, no sta-
tistically significant difference was seen for use of AD or
AX between lung cancer patients in the CT scan interven-
tion group and the control group, and with a very broad
confidence interval due to the limited number of cases.
Further adjustment for former use of AD or AX at base-
line did not change this finding. We did not make an add-
itional sub-analysis with exclusion at baseline of former
users of AD or AX, since the number of lung cancer cases
in the intervention group (n= 55) and in the control group
(n= 19) after this exclusion was small. All the sub-analyses
on persons diagnosed with lung cancer had too few cases
for proportional hazard regression analyses with adjust-
ment for the full model of confounders.Discussion
We found no indications that participation in a lung cancer
CT-screening program increases the risk of specific adversemental health outcomes, measured by prescription of AD
or AX as a proxy for medical conditions. At baseline,- an
individual day in the recruitment period,- the screened
study subjects did not differ from controls by gender, age
group, civil status, SES group, CCI group, or previous use
of AD or AX, and thus, the randomization was successful.
During follow-up no differences in the use of AD or AX
between the two groups were found. Our findings are in
line with a similar study investigating possible adverse
effects of participating in screening programs, but they
need cautious interpretation. [2] Although we found no in-
dication of an increased use of AD or AX in the interven-
tion group compared to the control group, our findings for
the present outcomes do not exclude an association for
other adverse effects. Bunge et al. found that participants
with a high affective risk perception showed higher lung
cancer-specific distress than participants with a low
affective risk perception, both at baseline and six months
after screening, and therefore attention for this specific
group was recommended. [4] The strengths of our study
were that comprehensive measures of potential confoun-
ders were available for the entire cohort. Furthermore,
complete and independent information on the chosen out-
come prescription of AD or AX and possible confounders
such as demographic factors and CCI were available for
the entire study population from the Danish registries.
A limitation of the present study was that we used pre-
scriptions of AD or AX as a proxy for medical conditions
without information of the underlying medical condition.
Since we expect, that only more severe degrees of depres-
sion and anxiety disorders were medically treated, our
study is not expected to include a milder degree of depres-
sion and anxiety disorders. Furthermore, the lack of infor-
mation of the underlying medical condition on the recipes
to clearly separate depressive disorders from anxiety disor-
ders, did not allow us to conclude on separate analyses of
AD and AX. In addition, it was a limitation that we were
not able to stratify for or adjust for personal characteristics
(robustness in personality and psychopathology) at base-
line, but we believe that randomization have reduced se-
lection bias due to this factor.
Whether the DLCST screening population is comparable
to the general Danish population of smokers or ex-smokers
, has been studied by Hestbech et al. by comparison with a
matched population sample. [6] Participants in DLCST
were found to have a higher socio-economic status and less
negative psychosocial aspects than the population sample,
together with differences regarding age, gender and geo-
graphical area. Therefore the participants of DLCST may
be more robust than the general population. The National
Lung Screening Trial (NLST) from the United States,
which showed a large reduction in mortality among
screened participants, also showed that participants were
better educated than a comparable sample from the general
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was found. [22,23] However, selection bias due to selected
recruitment at baseline has been shown, in a recent publi-
cation, not to play a major role for the risk estimates be-
tween psychosocial factors and AD and AX medication
during follow up. [24] Furthermore, we found that 30.90 %
of the cases and 31.38 % of the controls in the DLCST had
used AD or AX either before or during the follow-up
period. This does not point to a very robust participation
group, but needs to be studied in comparison with the pre-
scription pattern in an external reference group.
Conclusions
In conclusion, despite the use of several analytic strategies,
we found no indications that participation in a Danish
lung cancer CT-screening program lead to changes in pre-
scription of antidepressants and anxiolytic medications.
This indicates that CT screening in general does not cause
major psychological disturbances. However it may have
other psycho-social consequences not reflected in the pat-
tern of medications.
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